Nexxus Capital, a Mexico City-based private equity firm, has retained investment bank Greenhill & Co. to exit nutritional supplement developer Immunotec, CEO and Senior Managing Partner Roberto Langenauer said.

The PE firm estimates to close a deal in 2025, he said. However, depending on market conditions the firm will wait an additional time to maximize value for its investors, he said. Greenhill & Co. is a subsidiary of Tokyo-based commercial and investment banking group Mizuho.

Nexxus Capital first invested an undisclosed sum in Woodlands, Texas-based Immunotec in 2017 through its Nexxus VI fund. The PE firm owns a 77.6% stake in Immunotec, as reported.

Immunotec is focused on the development and commercialization of nutritional supplements through multi-level direct sales channels, according to a press release. The company researches and produces more than 20 different wellness products, aimed at strengthening immune systems, Langenauer said. Immunotec was founded in 1996 and has up to 200 employees, according to its LinkedIn profile.

Nexxus has helped Immunotec grow fourfold during the past seven years and now it is present in 17 countries across the Americas and Europe, he said. Recently, Spain became the third largest market for the company behind Mexico and the US, he added.